New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
08:24 EDTSTEMStemCells price target raised to $5.00 from $2.50 at Maxim
After reviewing StemCells' proof of concept data in an early dry-AMD trial, Maxim doubled its price target on the shares and said its new $5.00 target could still be conservative. The firm thinks dry-AMD has the potential to be a blockbuster opportunity that could be transformational for StemCells and keeps a Buy rating on the stock.
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
13:44 EDTSTEMStemCells says patent infringement case against Neuralstem dismissed by court
Subscribe for More Information
07:49 EDTSTEMNeuralstem awarded favorable court ruling in StemCell patent litigation
Subscribe for More Information
July 20, 2015
08:12 EDTSTEMStemCells transplants first patient in clinical trial for macular degeneration
StemCells announced that it has completed transplantation of the first subject in its Radiant Study at the Retina Foundation of the Southwest. The Phase II trial is designed to evaluate both the safety and efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of geographic atrophy, the most advanced form of dry age-related macular degeneration
07:33 EDTSTEMInternational AIDS Society to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use